2Katrib A,Smith MD,Ahern MJ,et al.Reduced chemokine and matrix metalloproteinase expression in patients with rheumatoid arthritis achieving remission.J Rheumatol,2003,30(1):10-21.
3Hamakawa H,Takemura M,Sato M,et al.Clinical significance of MMP-3 in patients with rheumatoid arthritis:comparison with other inflammatory markers (IL-6,IL-8).Rinsho Byori,2003,51(1):13-18.
4Yamanaka H,Matsuda Y,Tanaka M,et al.Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement,in patients with early rheumatoid arthritis.Arthritis Rheum,2001,44(12):2940-2941.
5Keyszer G,Lambiri I,Nagel R,et al.Circulating levels of matrix metalloproteinases MMP-3 and MMP-1,tissue inhibitor of metalloproteinases 1 (TIMP-1),and MMP-1/TIMP-1 complex in rheumatic disease.Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.J Rheumatol,1999,26(2):251-258.
7Okada Y,Nagase H,Harris ED Jr.Matrix metalloproteinases 1,2,and 3 from rheumatoid synovial cells are sufficient to destroy joints.J Rheumatol,1987,14 Spec:41-42.
8Ribbens C,Andre B,Kaye O,et al.Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not.Rheumatology (Oxford),2000,39(12):1357-1365.
二级参考文献28
1Yoon YS, Johnson IA, Park JS, et al. Therapeutic myocardial angiogenesis with vascular endothelial growth factor. Mol Cell Biochem, 2004, 264: 63-74.
2Bottomley MJ, Webb NJ, Watson CJ, et al. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid. Clin Exp Immunol, 1999,117:171-176.
4Bussolati B, Dunk C, Grohman M, et al. Vascular endothelial growth factor receptor-I modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol, 2001,159: 993-1008.
5Nagashima M, Yoshino S, lshiwata T, et al. The role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol, 1995, 22: 1624-1630.
6Pinney E, Liu K, Sheeman B, et al. Human three-dimentional fibroblast cultures express angiogenic activity. J Cell Physiol, 2000,183: 74-82.
7Harada M, Mitswyama K, Yoshida H, et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol, 1998,27:377-380.
8Maeno N, Takei S, Imanaka H. Increased circulating vascular endothelial growth factor is correlated with disease activity in polyarticular juvenile rheumatoid arthritis. J Rheumatol, 1999, 26:2244-2248.
9Ballara S, Peter C, Taylor PC, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum, 2001,44:2055-2064.
10Latour F, Zabraniecki L, Dromer C, et al. Does vascular endothelial growth factor in the rheumatoid synovium predict joint destruction: a clinical, radiological, and pathological study in 12 patients monitored for 10 years. Joint Bone Spine, 2001, 68: 493-498.
